Friday, Sep 22, 2023
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Education Today
    • Reviews
    • Property
    • Videos
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
Home | Business | Bharat Biotech Gets Dcgis Nod To Conduct Intranasal Booster Dose Trials

Bharat Biotech gets DCGI’s nod to conduct intranasal booster dose trials

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) had also recommended the internasal vaccine clinical trials during the last meeting.

By ANI
Updated On - 03:22 PM, Fri - 28 January 22
Bharat Biotech gets DCGI’s nod to conduct intranasal booster dose trials
whatsapp facebook twitter telegram

New Delhi: The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) had also recommended the internasal vaccine clinical trials during the last meeting.

The NOC letter issued by the DCGI read, “Central Licensing Authority hereby permits Bharat Biotech International limited to conduct clinical trials of the new drug or investigational new drug.”

The dosage form of the vaccine is liquid for the intranasal route of administration and every single dose contains 0.5ml.

The trials of the Intranasal vaccine will take place at nine different sites of the country.

The trials will be conducted at Atman Hospital, Ahmedabad, Gujarat; AIIMS, Delhi and Patna; Oyster and Pearls Hospitals, Pune; Pt.BD Sharma Postgraduate Institute of Medical Sciences at Rohtak, Haryana; Acharya Vinobha Bhave Rural Hospital, Wardha; Jeevan Rekha Hospital, Belagavi; Rana hospital, Gorakhpur; and Prakhar Hospital, Uttar Pradesh.

“The Phase -3 clinical trial should be conducted as per protocol multi-center study to compare immunogenicity and safety of BBV154 with COVAXIN.” read the letter.

Telangana Today Whatsapp
  • Follow Us :
  • Tags
  • Bharat Biotech
  • DCGI
  • dose trials
  • Hyderabad

Related News

  • Telangana: Nine DSP (Civil) rank officers transferred

    Telangana: Nine DSP (Civil) rank officers transferred

  • Sunshine record big win in HCA C Division one-day league

    Sunshine record big win in HCA C Division one-day league

  • Hyderabad’s Biju shoots gold

    Hyderabad’s Biju shoots gold

  • IMD issues yellow alert for Northeastern Telangana, anticipates heavy rainfall

    IMD issues yellow alert for Northeastern Telangana, anticipates heavy rainfall

  • Shorter GRE is available now

    Shorter GRE is available now

  • ‘Falls Prevention Experience Centre’ inaugurated at LV Prasad Eye Institute

    ‘Falls Prevention Experience Centre’ inaugurated at LV Prasad Eye Institute

Latest News

  • DEET: End your Job search here

    3 hours ago
  • India vs Australia 1st ODI Highlights: Rahul And Surya Deal The Chase Calmly

    3 hours ago
  • Editorial: Onus on Ottawa

    3 hours ago
  • Prize money for ICC Men’s Cricket World Cup 2023 revealed

    3 hours ago
  • Karnataka govt. says it is committed to protect state’s interest in Cauvery issue

    3 hours ago
  • India vs Australia 1st ODI Highlights: Zampa Attempts To Control India’s Chase

    3 hours ago
  • Jairam Ramesh demands suspension of BJP MP Bidhuri over remarks

    3 hours ago
  • Opinion: Why slowing China worries West

    3 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam